Neuronal immunoexpression and a distinct subtype of adult primary supratentorial glioblastoma with a better prognosis: Clinical article

Journal of Neurosurgery

Volumn 117, Issue 3, 2012, Pages 476-485

  Pallud, Johan ^a,b   Dezamis, Edouard ^a,b   Audureau, Etienne ^b,c   Devaux, Bertrand ^a,b   Souillard Scemama, Raphaëlle ^a,b   Sanai, Nader ^d   Page, Philippe ^a,b   Beuvon, Frédéric ^a,b   Koziak, Maria ^a,b   Oppenheim, Catherine ^a,b   Dhermain, Frédéric ^e   Schlienger, Michel ^f   Meder, Jean François ^a,b   Roux, François Xavier ^a,b   Varlet, Pascale ^a,b  

^a CENTRE HOSPITALIER SAINTE ANNE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Institut Cochin   (France)

^d BARROW NEUROLOGICAL INSTITUTE   (United States)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f HÔPITAL TENON   (France)

Author keywords

Glioblastoma; Immunoexpression; Neurofilament protein; Oncology; Prognosis; Progression free survival

Indexed keywords

NEUROFILAMENT PROTEIN; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; NEUROFILAMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TEMPORAL LOBE; TREATMENT OUTCOME; TUMOR CELL; TUMOR LOCALIZATION;

ADULT; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; DRUG THERAPY; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUROFILAMENT PROTEINS; NEURONS; NEUROSURGICAL PROCEDURES; PROGNOSIS; RADIOTHERAPY; RETROSPECTIVE STUDIES; SUPRATENTORIAL NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84865847256     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2012.5.JNS111670     Document Type: Article

References (29)

1. Bauchet L, Mathieu-Daudé H, Fabbro-Peray P, Rigau V, Fabbro M, Chinot O, et al: Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004. Neuro Oncol 12:725-735, 2010
2. Blümcke I, Becker AJ, Normann S, Hans V, Riederer BM, Krajewski S, et al: Distinct expression pattern of microtubule-associated protein-2 in human oligodendrogliomas and glial precursor cells. J Neuropathol Exp Neurol 60:984-993, 2001
3. Donev K, Scheithauer BW, Rodriguez FJ, Jenkins S: Expression of diagnostic neuronal markers and outcome in glioblastoma. Neuropathol Appl Neurobiol 36:411-421, 2010
4. Ducray F, de Reyniès A, Chinot O, Idbaih A, Figarella-Branger D, Colin C, et al: An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patients. Mol Cancer 9:234-250, 2010
5. Fontaine D, Paquis P: [Glioblastoma: clinical, radiological and biological prognostic factors.] Neurochirurgie 56:467-476, 2010 (Fr)
6. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003, 2005 (Pubitemid 40349502)
7. Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, et al: Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 26:4189-4199, 2008
8. Kappadakunnel M, Eskin A, Dong J, Nelson SF, Mischel PS, Liau LM, et al: Stem cell associated gene expression in glioblastoma multiforme: relationship to survival and the subventricular zone. J Neurooncol 96:359-367, 2010
9. Kozak KR, Mahadevan A, Moody JS: Adult gliosarcoma: epidemiology, natural history, and factors associated with outcome. Neuro Oncol 11:183-191, 2009
10. Kozak KR, Moody JS: Giant cell glioblastoma: a glioblastoma subtype with distinct epidemiology and superior prognosis. Neuro Oncol 11:833-841, 2009
11. Liang Y, Diehn M, Watson N, Bollen AW, Aldape KD, Nicholas MK, et al: Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci U S A 102:5814-5819, 2005 (Pubitemid 40559642)
12. Lim DA, Cha S, Mayo MC, Chen MH, Keles E, VandenBerg S, et al: Relationship of glioblastoma multiforme to neural stem cell regions predicts invasive and multifocal tumor phenotype. Neuro Oncol 9:424-429, 2007
13. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97-109, 2007 (Pubitemid 47103521)
14. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H: IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 15:6002-6007, 2009
15. Park JK, Hodges T, Arko L, Shen M, Dello Iacono D, McNabb A, et al: Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol 28:3838-3843, 2010
16. Patru C, Romao L, Varlet P, Coulombel L, Raponi E, Cadusseau J, et al: CD133, CD15/SSEA-1, CD34 or side populations do not resume tumor-initiating properties of long-term cultured cancer stem cells from human malignant glio-neuronal tumors. BMC Cancer 10:66-77, 2010
17. Perry A, Miller CR, Gujrati M, Scheithauer BW, Zambrano SC, Jost SC, et al: Malignant gliomas with primitive neuroectodermal tumor-like components: a clinicopathologic and genetic study of 53 cases. Brain Pathol 19:81-90, 2009
18. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, et al: Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157-173, 2006 (Pubitemid 43357943)
19. Prayson RA, Abramovich CM: Glioneuronal tumor with neuropil-like islands. Hum Pathol 31:1435-1438, 2000
20. Rich JN, Hans C, Jones B, Iversen ES, McLendon RE, Rasheed BK, et al: Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res 65:4051-4058, 2005 (Pubitemid 40775641)
21. Rivera AL, Pelloski CE, Gilbert MR, Colman H, De La Cruz C, Sulman EP, et al: MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol 12:116-121, 2010 (Erratum in Neuro Oncol 12:617, 2010)
22. Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, et al: Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27:4150-4154, 2009
23. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005 (Pubitemid 40349501)
24. Teo JG, Gultekin SH, Bilsky M, Gutin P, Rosenblum MK: A distinctive glioneuronal tumor of the adult cerebrum with neuropil-like (including "rosetted") islands: report of 4 cases. Am J Surg Pathol 23:502-510, 1999 (Pubitemid 29214951)
25. Varlet P, Soni D, Miquel C, Roux FX, Meder JF, Chneiweiss H, et al: New variants of malignant glioneuronal tumors: a clinicopathological study of 40 cases. Neurosurgery 55:1377-1392, 2004
26. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al: Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98-110, 2010
27. Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, Schramm J, et al: Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 27:5743-5750, 2009
28. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al: IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765-773, 2009
29. Young GS, Macklin EA, Setayesh K, Lawson JD, Wen PY, Norden AD, et al: Longitudinal MRI evidence for decreased survival among periventricular glioblastoma. J Neurooncol 104:261-269, 2011